1. EXTH-102. PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETICS (PK) OF MIRDAMETINIB IN A NON-HUMAN PRIMATE (NHP) MODEL. (14th November 2022) Authors: McCully, Cynthia Lester; Shearer, Todd; Gross, Andrea; Langseth, Abraham; Peer, Cody; Killoran, Kristin; Garcia, Rafael Cruz; Figg, William; Widemann, Brigitte Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). (3rd June 2022) Authors: Vinitsky, Anna; Chiang, Jason; Bag, Asim K; Campagne, Olivia; Stewart, Clinton F; Dunphy, Paige; Shulkin, Barry; Li, Qian; Lin, Tong; Hoehn, Mary Ellen; Johnson, Jason N; Towbin, Jeffrey A; Khan, Raja; Tatevossian, Ruth G; Armstrong, Gregory T; Potter, Brian; Conklin, Heather; Shearer, Todd; Scot... Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 1 Page Start: i92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗